Urogen

Covid-19 adds a new danger to drug launches
Covid-19 adds a new danger to drug launches
EP Vantage
drug launches
pandemic
COVID-19
Esperion
Biohaven
Urogen
Flag link:
UroGen Gets FDA Nod for Low-Grade Upper Tract Urothelial Cancer Drug
UroGen Gets FDA Nod for Low-Grade Upper Tract Urothelial Cancer Drug
Xconomy
Urogen
urothelial cancer
FDA
Jelmyto
Flag link:
The Week Ahead In Biotech: Spotlight On ESMO Conference
The Week Ahead In Biotech: Spotlight On ESMO Conference
Yahoo/Benzinga
JNJ
daratumumab
Urogen
Rhythm Pharmaceuticals
Anavex
Aravive Biologics
TrovaGene
Incyte
AstraZeneca
Roche
Amgen
Aslan
G1 Therapeutics
GSK
Calithera Biosciences
Seattle Genetics
Immunomedics
Checkpoint Therapeutics
Aileron Therapeutics
Genocea Biosciences
AbbVie
Zymeworks
Flag link:
UroGen, Wave each raise $150M follow-ons
UroGen, Wave each raise $150M follow-ons
BioCentury
Urogen
Wave Life Sciences
Flag link:
As Barrett steps in as CEO, UroGen reports 57% complete response rate for urothelial cancer therapy
As Barrett steps in as CEO, UroGen reports 57% complete response rate for urothelial cancer therapy
BioCentury
Urogen
UGN-101
MitoGel
urothelial cancer
Liz Barrett
Flag link:
Why did Liz Barrett turn her back on a top job at Novartis in exchange for the helm of a biotech you never heard of?
Why did Liz Barrett turn her back on a top job at Novartis in exchange for the helm of a biotech you never heard of?
Endpoints
Liz Barrett
Novartis
Urogen
Flag link:
Upcoming events – Phase III readouts loom for Urogen and Mediwound
Upcoming events – Phase III readouts loom for Urogen and Mediwound
EP Vantage
Urogen
clinical trials
UGN-101
urothelial cancer
MediWound
NexoBrid
devices
burns
Flag link: